Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,587Revenue (TTM) $M215Net Margin (%)42.4Altman Z-Score9.2
Enterprise Value $M1,501EPS (TTM) $1.7Operating Margin %25.2Piotroski F-Score7
P/E(ttm)18.9Beneish M-Score-1.5Pre-tax Margin (%)23.4Higher ROA y-yY
Price/Book8.410-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsN
Price/Sales7.85-y EBITDA Growth Rate %--Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow25.9y-y EBITDA Growth Rate %182ROA % (ttm)38.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)63.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M50.2ROIC % (ttm)117Gross Margin Increase y-yY

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SUPN is held by these investors:



SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PATRICK GREGORY SVP, CFO 2016-09-16Sell2,000$2530view
PATRICK GREGORY SVP, CFO 2016-07-14Sell3,395$2247.73view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2016-04-11Sell30,762$16.4997.09view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-12-09Sell14,238$14.9118.12view
BARRETT M JAMESDirector 2015-12-08Sell212,970$14.56123.21view
BARRETT M JAMESDirector 2015-11-25Sell16,179$16.3598.78view
BARRETT M JAMESDirector 2015-11-18Sell93,000$16.6195.67view
BARRETT M JAMESDirector 2015-11-16Sell119,650$16.24100.12view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-11-04Sell5,000$19.963.32view
Schwabe Stefan K.F.Executive Vice President R&D 2015-07-28Sell2,350$21.253.3view

Press Releases about SUPN :

Quarterly/Annual Reports about SUPN:

News about SUPN:

Articles On GuruFocus.com
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adol Apr 05 2017 
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation Mar 07 2017 
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation Mar 06 2017 
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
Harry Boxer’s momentum stocks to watch: 3 biotechs, 1 retailer Apr 19 2017
This Biotech Leader Breaks Out, Defying Sector Odds Apr 18 2017
Supernus Drug Gets Label Expansion for Migraines Apr 06 2017
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and... Apr 05 2017
3 Highest Growth Stocks in the Market Today Mar 29 2017
Ultragenyxs’ Seizure Drug Fails Study Mar 23 2017
Supernus Pharma Tanks on Settlement of Two Patent Disputes (SUPN) Mar 08 2017
These Pharma Stocks Are Big Losers From Trump's Drug-Pricing Tweet Mar 07 2017
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation Mar 07 2017
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation Mar 06 2017
ETFs with exposure to Supernus Pharmaceuticals, Inc. : March 6, 2017 Mar 06 2017
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Mar 03 2017
Edited Transcript of SUPN earnings conference call or presentation 1-Mar-17 2:00pm GMT Mar 01 2017
Supernus tops Street 4Q forecasts Mar 01 2017
Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results Feb 28 2017
Supernus to Present at Cowen Health Care Conference in March Feb 27 2017
Will Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week? Feb 24 2017
Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call Feb 13 2017
Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR® Feb 08 2017
Top 4 Pharmaceutical Stocks for 2017 Jan 30 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)